Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 7/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 7/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 6/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.36 |
| ▸ | BRAF | P15056 | 5/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | GCGR | P47871 | 1/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.35 |
| ▸ | RAF1 | P04049 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.34 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | FLT4 | P35916 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | MATK | P42679 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68118 | 0.79 | CDK8 (0.42) | MAPK14MAPK13MAPK12MAPK11BRAF | |
| SCHEMBL68361 | 0.79 | BRAF (0.40) | MAPK14MAPK13MAPK12MAPK11BRAF | |
| SCHEMBL67221 | 0.77 | SPR (0.38) | MAPK14MAPK13MAPK12MAPK11BRAF | |
| SCHEMBL70235 | 0.77 | BRAF (0.40) | MAPK14MAPK13MAPK12MAPK11BRAF | |
| SCHEMBL68130 | 0.76 | MAPK14 (0.40) | MAPK14MAPK13MAPK12MAPK11BRAF | |
| SCHEMBL67180 | 0.71 | MAPK14 (0.46) | MAPK14MAPK13MAPK12MAPK11BRAF | |
| SCHEMBL13693148 | 0.68 | MAPK14 (0.37) | MAPK14MAPK13MAPK12MAPK11BRAF | |
| SCHEMBL13693286 | 0.68 | MAPK14 (0.37) | MAPK14MAPK13MAPK12MAPK11BRAF | |
| SCHEMBL13693361 | 0.68 | MAPK14 (0.44) | MAPK14MAPK13MAPK12MAPK11BRAF | |
| SCHEMBL66711 | 0.67 | BRAF (0.46) | MAPK14MAPK13MAPK12MAPK11BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865732-B2 | Heterocyclic compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-8865732-B2 | Heterocyclic compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | NOVARTIS AG (CH) | 2013-08-15 | — | — | US | disclosed |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | NOVARTIS AG (CH) | 2013-08-15 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
| WO-2009115572-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND USES THEROF | NOVARTIS AG (CH) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | TLR8 3899/4885TLR7 4161/4885TLR9 4720/4885 |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | BRAF, RAF1, HRAS | TLR8 4357/4885TLR7 4372/4885TLR9 4855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.